

CORRECTED VERSION

(19) World Intellectual Property  
Organization  
International Bureau



WIPO | PCT



(10) International Publication Number  
**WO 2016/024205 A8**

(43) International Publication Date  
18 February 2016 (18.02.2016)

- (51) **International Patent Classification:**  
C12N 15/11 (2006.01) C12N 15/113 (2010.01)
- (21) **International Application Number:** PCT/IB2015/056080
- (22) **International Filing Date:** 10 August 2015 (10.08.2015)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:** 62/037,741 15 August 2014 (15.08.2014) US
- (71) **Applicant:** PFIZER INC. [US/US]; 235 East 42nd Street, New York, New York 10017 (US).
- (72) **Inventors:** JENSEN, Mads Aaboe; Duemosepark 149, DK-3520 Farum (DK). LINDOW, Morten; Thomas Koppels Alle 22C, DK-2450 Copenhagen SV (DK).
- (74) **Agent:** OLSON, A. Dean; Pfizer Worldwide Research & Development, Eastern Point Road MS8260-2141, Groton, Connecticut 06340 (US).
- (81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
- (84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
- Declarations under Rule 4.17:**
- as to the identity of the inventor (Rule 4.17(i))
  - as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
  - as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))
- Published:**
- with international search report (Art. 21(3))
  - with sequence listing part of description (Rule 5.2(a))
- (48) **Date of publication of this corrected version:** 20 October 2016
- (15) **Information about Correction:** see Notice of 20 October 2016



WO 2016/024205 A8

(54) **Title:** OLIGOMERS TARGETING HEXANUCLEOTIDE REPEAT EXPANSION IN HUMAN C9ORF72 GENE

(57) **Abstract:** The disclosure relates to oligomers capable of targeting RNA expressed from the human C9ORF72 gene containing a pathogenic hexanucleotide repeat expansion. Such oligomers are useful for, among other things, reducing or eliminating C9ORF72 RNA and/or proteins translated therefrom, and treating or preventing diseases or disorders caused by, or associated with, hexanucleotide repeat expansion, including familial frontotemporal dementia (FTD) and familial amyotrophic lateral sclerosis (ALS).